Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6620817 | 0.87 | SIGMAR1 (0.48) | SIGMAR1 | |
| SCHEMBL11775261 | 0.81 | SIGMAR1 (0.63) | SIGMAR1 | |
| SCHEMBL5493423 | 0.75 | DRD3 (0.55) | SIGMAR1 | |
| SCHEMBL5240929 | 0.75 | SIGMAR1 (0.47) | SIGMAR1 | |
| SCHEMBL9868061 | 0.74 | SIGMAR1 (0.73) | SIGMAR1 | |
| SCHEMBL5498350 | 0.74 | DRD4 (0.46) | SIGMAR1 | |
| SCHEMBL5493145 | 0.74 | HDAC1 (0.46) | SIGMAR1 | |
| SCHEMBL16752776 | 0.74 | DRD2 (0.53) | SIGMAR1 | |
| SCHEMBL6213626 | 0.74 | DRD2 (0.53) | SIGMAR1 | |
| Hydrochloric Acid SCHEMBL9865080 | 0.73 | SIGMAR1 (0.71) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1178047-B1 | Diazabicyclooctane derivatives and therapeutic uses thereof | PFIZER PROD INC (US) | 2004-02-25 | — | — | EP | claimed |
| US-6531468-B2 | Inhibiting serotonin reuptake in the central nervous system of a mammal | PFIZER INC | 2003-03-11 | — | — | US | claimed |
| US-20020068748-A1 | Diazabicyclooctane derivatives and therapeutic uses thereof | PFIZER INC. | 2002-06-06 | — | — | US | claimed |
| EP-1178047-A1 | Diazabicyclooctane derivatives and therapeutic uses thereof | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | claimed |
| EP-1178048-B1 | Azabicycloalkane derivatives for use as serotonin reuptake inhibitors and 5HT2a antagonists | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1178047-B1 | Diazabicyclooctane derivatives and therapeutic uses thereof | PFIZER PROD INC (US) | 2004-02-25 | — | — | EP | disclosed |
| US-6552015-B2 | Inhibition of serotonin reuptake; especially 2-(azabicycloalkyl)alkylenyl)isoquinolin-3-one compounds | PFIZER INC. | 2003-04-22 | — | — | US | disclosed |
| US-6531468-B2 | Inhibiting serotonin reuptake in the central nervous system of a mammal | PFIZER INC | 2003-03-11 | — | — | US | disclosed |
| US-20020068748-A1 | Diazabicyclooctane derivatives and therapeutic uses thereof | PFIZER INC. | 2002-06-06 | — | — | US | disclosed |
| US-20020052355-A1 | Azabicycloalkane derivatives and therapeutic uses thereof | PFIZER PRODUCTS INC. | 2002-05-02 | — | — | US | disclosed |
| EP-1178047-A1 | Diazabicyclooctane derivatives and therapeutic uses thereof | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | disclosed |
| EP-1178048-A1 | Azabicycloalkane derivatives for use as serotonin reuptake inhibitors and 5HT2a antagonists | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068748-A1 | Diazabicyclooctane derivatives and therapeutic uses thereof | CNR1, CBR1, CLIC1 | SIGMAR1 174/4885 |
| US-20020052355-A1 | Azabicycloalkane derivatives and therapeutic uses thereof | HTR5A, HTR1A, HTR2A | SIGMAR1 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.